Document
type: Class

Academic Article
type: Class

Continuant
type: Class

Entity
type: Class

individual
rights: termsOfUse
date: 2026-08-24T09:42:45
publisher: Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
type: Document
label: RDF description of Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial - http://irises.unisr.it/resource/item/223089

Generically Dependent Continuant
type: Class

Article
type: Class

Inglese
type: Language

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
type: Generically Dependent Continuant
type: Continuant
type: Entity
type: Document
type: Article
related by: 358771669
type: Information Content Entity
language: Inglese
type: Thing
type: Academic Article
most specific type: Academic Article

Information Content Entity
type: Class

358771669
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial